Clinical trials: Advanced Solid Tumors With MTAP Deletion
Solid Tumors
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion.
- Trial name
- NCT07492680
- Testing
- BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC
- Where
- 58 sites in United States, Belgium and 11 more
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC)
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
This is a Phase Ib, open-label, multicenter study of HSK41959 tablets in combination with standard therapy in patients with MTAP-deficient advanced solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
- Trial name
- NCT07699757
- Testing
- HSK41959, Sintilimab, Pemetrexed + Cisplatin /Carboplatin
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Advanced Solid Tumors, Lymphoma
Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma
The purpose of this study is to identify subjects with advanced solid tumors or lymphoma in which the methylthioadenosine phosphorylase (MTAP) protein has been lost.
- Trial name
- NCT03361358
- Where
- 3 sites in United States, Spain
- Volunteers
- 44 people
- Sponsor
- Agios Pharmaceuticals, Inc.
MTAP Deletion
A Study of HS-10587 in Patients With Advanced Solid Tumors
This is a Phase I, multicenter, open-label clinical trial with dose escalation/dose expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and antitumor efficacy…
- Trial name
- NCT07567859
- Testing
- HS-10587
- Volunteers
- 362 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability and drug levels of Navlimetostat (BMS-986504) in participants with advanced solid tumors.
- Trial name
- NCT07077434
- Testing
- BMS-986504
- Where
- 12 sites in China, Japan
- Volunteers
- 32 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor, Solid Tumors
A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors
This is a first-in-human clinical study of PEP08, a novel cancer therapy being evaluated both as monotherapy and in combination with other treatments in patients with advanced or metastatic solid tumors harboring MTAP deletion.
- Conditions
- Advanced Solid Tumor, Solid Tumors, MTAP-deleted Solid Tumors, MTAP Deletion
- Trial name
- NCT06973863
- Testing
- PEP08
- Where
- 4 sites in Australia, Taiwan
- Volunteers
- 40 people
- Sponsor
- PharmaEngine
Advanced or Metastatic MTAP-deleted Solid Tumors
An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors
This study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it…
- Trial name
- NCT06568614
- Testing
- BG-89894
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 29 people
- Sponsor
- BeOne Medicines
Solid Tumor Malignancies
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
This study employs a non-randomized, open-label design to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of DC50292A tablets in patients with MTAP-deficient advanced or metastatic solid…
- Trial name
- NCT07071090
- Testing
- DC50292A
- Where
- 8 sites in China
- Volunteers
- 32 people
- Sponsor
- Heronova Pharmaceuticals
Advanced Solid Tumors
Study of GS-2426 in Participants With Advanced Solid Tumors
The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors.
- Trial name
- NCT07601243
- Testing
- GS-2426
- Where
- 6 sites in United States, Spain
- Volunteers
- 174 people
- Sponsor
- Gilead Sciences
Locally Advanced/Metastatic Solid Tumors
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants…
- Trial name
- NCT06414460
- Testing
- ISM3412
- Where
- 10 sites in United States, China
- Volunteers
- 146 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Advanced Solid Tumors, Lymphoma
Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-270 in participants with advanced solid tumors or lymphoma with homozygous MTAP deletion.
- Trial name
- NCT03435250
- Testing
- AG-270, docetaxel, nab-paclitaxel
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 123 people
- Sponsor
- Institut de Recherches Internationales Servier
Locally Advanced Solid Tumor
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion…
- Trial name
- NCT05732831
- Testing
- TNG462, Pembrolizumab
- Where
- 26 sites in United States, France and 1 more
- Volunteers
- 225 people
- Sponsor
- Tango Therapeutics, Inc.
Advanced Solid Tumors
Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK41959 when given orally in patients with MTAP Deletion locally advanced or metastatic Solid Tumors.
- Trial name
- NCT06968572
- Testing
- HSK41959
- Where
- 3 sites in China
- Volunteers
- 245 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
This is a phase I, open-label, first-in-human study of CS08399, comprising two phases: dose escalation (including single-dose and multiple-dose) and cohort expansion.
- Conditions
- Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma
- Trial name
- NCT07583771
- Testing
- CS08399
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Mesothelioma, Non Small Cell Lung Cancer
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the…
- Conditions
- Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor
- Trial name
- NCT05245500
- Testing
- MRTX1719
- Where
- 25 sites in United States
- Volunteers
- 336 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with sacituzumab govitecan (SG), in adult…
- Trial name
- NCT04794699
- Testing
- IDE397, Sacituzumab govitecan
- Where
- 37 sites in United States, Australia and 5 more
- Volunteers
- 169 people
- Sponsor
- IDEAYA Biosciences
MTAP-deleted Solid Tumors
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have…
- Trial name
- NCT06188702
- Testing
- S095035, TNG462
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 61 people
- Sponsor
- Servier Bio-Innovation LLC
Locally Advanced Solid Tumor
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion…
- Trial name
- NCT05275478
- Testing
- TNG908
- Where
- 20 sites in United States, France
- Volunteers
- 110 people
- Sponsor
- Tango Therapeutics, Inc.
Advanced Solid Tumors With MTAP Deletion
A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors（G-MAP 101）
This is a multicenter, single-arm, open-label, dose-escalation, dose-expansion study to evaluate the safety, tolerability, PK/PD, and preliminary anti-tumor activity of GH56 Capsule in subjects with advanced solid tumors who have…
- Trial name
- NCT06796699
- Testing
- GH56 Capsule
- Where
- 25 sites in China
- Volunteers
- 200 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.